Arcus Biosciences ROA 2017-2022 | RCUS
Current and historical return on assets (ROA) values for Arcus Biosciences (RCUS) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Arcus Biosciences ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2022-12-31 |
$-0.27B |
$1.35B |
-18.54% |
| 2022-09-30 |
$0.08B |
$1.39B |
5.33% |
| 2022-06-30 |
$0.07B |
$1.48B |
4.92% |
| 2022-03-31 |
$0.06B |
$1.54B |
4.76% |
| 2021-12-31 |
$0.05B |
$1.59B |
4.97% |
| 2021-09-30 |
$-0.28B |
$0.84B |
-32.39% |
| 2021-06-30 |
$-0.20B |
$0.90B |
-23.30% |
| 2021-03-31 |
$-0.17B |
$0.94B |
-22.41% |
| 2020-12-31 |
$-0.12B |
$0.77B |
-21.96% |
| 2020-09-30 |
$-0.09B |
$0.81B |
-21.07% |
| 2020-06-30 |
$-0.11B |
$0.48B |
-41.60% |
| 2020-03-31 |
$-0.10B |
$0.18B |
-45.51% |
| 2019-12-31 |
$-0.09B |
$0.20B |
-37.04% |
| 2019-09-30 |
$-0.08B |
$0.22B |
-32.32% |
| 2019-06-30 |
$-0.07B |
$0.24B |
-26.04% |
| 2019-03-31 |
$-0.06B |
$0.26B |
-19.73% |
| 2018-12-31 |
$-0.05B |
$0.28B |
-17.23% |
| 2018-09-30 |
$-0.05B |
$0.29B |
-18.96% |
| 2018-06-30 |
$-0.06B |
$0.29B |
-31.94% |
| 2018-03-31 |
$-0.06B |
$0.31B |
-47.68% |
| 2017-12-31 |
$-0.05B |
$0.19B |
-111.58% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.194B |
$0.112B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
